The three Sopharma AD factories - the one in Kazanlak, the Tablet production and Ampoule production in Sofia - have Nivalin in common, one of the strongest Sopharma products. Nivalin is sold in more than 10 countries outside Bulgaria, making it one of the most famous Sopharma products. It increases the intensity of the reflex centers of the spinal cord, medulla oblongata and cerebral cortex, thus influences all links of the reflex arc.
Sofia, Bulgaria, July 22, 2024 – According to the requirements of art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies that for June 2024 the Company recorded a decrease in sales of 35% compared to the same month of the previous year, incl. 7% decrease in domestic sales and 49% decrease in export sales.
For the first six months of 2024, the Company recorded a decrease in sales of 8%, incl. 4% increase of domestic sales and 15% decrease in export sales.
Sofia, Bulgaria, July 1, 2024 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 27, 2024 the Company sold 7 000 (seven thousand) repurchased own shares representing 0.004% of the share capital of the Company, at a total value of BGN 41 860,00 on the Bulgarian Stock Exchange, the average price per share was BGN 5,98.
Sofia, Bulgaria, June 28, 2024 – In accordance with the requirements of art. 115c, para. 4 of LPOS “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies all shareholders of the Company about the decision of the AGM of “Sopharma” AD that took place on June 28, 2024 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:
The AGM approves the proposal by the Board of Directors for the distribution of gross dividend at the amount of BGN 0.09 /nine stotinki / per share.
